Study protocol for a multi-center, prospective Parkinson's disease registry in Iran

Document Type : Original Article

Authors

1 Clinical Research Development Unit, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran Iran

4 Department of Functional Neurosurgery, Medical School, Isfahan University of Medical Science, Isfahan, Iran

5 Student Research Committee, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Shahid Beheshti Medical University, Tehran, Iran

Abstract
Background: Parkinson's disease (PD) is a globally prevalent neurodegenerative condition that requires accurate diagnosis and tailored treatments. Despite the rising prevalence of PD in Iran, there has historically been a lack of standardized, multi-center data infrastructure to comprehensively record disease features, progression, and treatment results in this population. To address this gap, we present the Shahid Beheshti Medical University Parkinson's Disease Registry (SBMU-PDR).
Methods: The SBMU-PDR is a multi-center, prospective, observational registry established in 2020, with enrollment ongoing through 2026. The registry is designed to collect and analyze comprehensive data from patients with PD. Standardized forms were used to gather information on demographics, medication history, comorbidities, and the severity of motor and non-motor symptoms at baseline and during six-year follow-up visits. Data integrity and ethical compliance are maintained through specialized committees.
Results: The SBMU-PDR's well-defined protocol ensures consistent data collection, thereby minimizing errors, enhancing data reliability, and facilitating comparison across different registries. With a focus on inclusivity, SBMU-PDR aims to elucidate PD risk factors, demographic characteristics, and clinical profiles among a substantial patient cohort, facilitate early detection, and contribute to improved patient outcomes. Measurable outcomes include disease progression, frequency and types of treatment, and cohort-level demographic and risk-factor distributions.
The registry's extensive data pool serves as a valuable resource for advancing research initiatives, refining patient care, and contributing to the understanding of PD's intricate nature.
Conclusion: The SBMU-PDR project signifies a paradigm shift in PD registry methodologies, offering a valuable tool for advancing scientific understanding in the realm of movement disorders.

Keywords

Subjects

1.     GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17(11): 939-53.
2.     Wu AD, Wilson AM. Parkinson's disease population-wide registries in the United States: Current and future opportunities. Front Digit Health 2023; 5: 1149154.
3.     Soman K, Nelson CA, Cerono G, Goldman SM, Baranzini SE, Brown EG. Early detection of Parkinson's disease through enriching the electronic health record using a biomedical knowledge graph. Front Med (Lausanne) 2023; 10: 1081087.
4.     Gliklich RE, Dreyer NA, Leavy MB, editors. Registries for Evaluating Patient Outcomes: A User's Guide. Rockville, MD: Agency for Healthcare Research and Quality (US); 2014.
5.     Bardien S, Carr J. A model PD registry for countries with limited resources. Nat Rev Neurol 2020; 16(10): 523-4.
6.     Safiri S, Noori M, Nejadghaderi SA, Mousavi SE, Sullman MJM, Araj-Khodaei M, et al. The burden of Parkinson's disease in the Middle East and North Africa region, 1990-2019: results from the global burden of disease study 2019. BMC Public Health 2023; 23(1): 107.
7.     De Roos P, Bloem BR, Kelley TA, Antonini A, Dodel R, Hagell P, et al. A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. J Parkinsons Dis 2017; 7(3): 533-43.
8.     Zhou X, Liu Z, Zhou X, Xiang Y, Zhou Z, Zhao Y, et al. The Chinese Parkinson's Disease Registry (CPDR): Study Design and Baseline Patient Characteristics. Mov Disord 2022; 37(7): 1335-45.
9.     Chitsaz A, Ajami S, Varnaseri M. Establishing a minimum data set for Parkinson's (PMDS) in Iran. J Educ Health Promot 2022; 11: 324.
10.  Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30(12): 1591-601.
11.  Meinders MJ, Donnelly AC, Sheehan M, Bloem BR. Including People with Parkinson's Disease in Clinical Study Design and Execution: A Call to Action. J Parkinsons Dis 2022; 12(4): 1359-63.
12.  Kim A, Yang HJ, Kwon JH, Kim MH, Lee J, Jeon B. Mortality of Deep Brain Stimulation and Risk Factors in Patients With Parkinson's Disease: A National Cohort Study in Korea. J Korean Med Sci 2023; 38(3): e10.
13.  Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, et al. Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort? Parkinsonism Relat Disord 2019; 64: 226-34.
14.  Bhidayasiri R, Wannachai N, Limpabandhu S, Choeytim S, Suchonwanich Y, Tananyakul S, et al. A national registry to determine the distribution and prevalence of Parkinson's disease in Thailand: implications of urbanization and pesticides as risk factors for Parkinson's disease. Neuroepidemiology 2011; 37(3-4): 222-30.
15.  Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch Neurol 2012; 69(3): 380-4.
16.  Goldman SM, Marek K, Ottman R, Meng C, Comyns K, Chan P, et al. Concordance for Parkinson's disease in twins: A 20-year update. Ann Neurol 2019; 85(4): 600-5.
17.  Ojo OO, Abubakar SA, Iwuozo EU, Nwazor EO, Ekenze OS, Farombi TH, et al. The Nigeria Parkinson Disease Registry: Process, Profile, and Prospects of a Collaborative Project. Mov Disord 2020; 35(8): 1315-22.
18.  Fereshtehnejad SM, Shafieesabet M, Rahmani A, Delbari A, Lökk J. Medium-to-high prevalence of screening-detected parkinsonism in the urban area of Tehran, Iran: data from a community-based door-to-door study. Neuropsychiatr Dis Treat 2015; 11: 321-32.
19.  Khedr EM, Al Attar GS, Kandil MR, Kamel NF, Abo Elfetoh N, Ahmed MA. Epidemiological study and clinical profile of Parkinson's disease in the Assiut Governorate, Egypt: a community-based study. Neuroepidemiology 2012; 38(3): 154-63.
20.  Alrefai A, Habahbih M, Alkhawajah M, Darwish M, Batayha W, Khader Y, et al. Prevalence of Parkinson's disease in Northern Jordan. Clin Neurol Neurosurg 2009; 111(10): 812-5.
21.  Khalil H, Shraim M, Jaradat B, Ibrahim RH, Kamel WA, Khan S, et al. Parkinson's Disease Database in the Middle East, North Africa, and South Asia Countries. Int J Public Health 2025; 70: 1608016.

Articles in Press, Accepted Manuscript
Available Online from 17 November 2026